mRNA vaccine in cancer therapy: Current advance and future outlook
Youhuai Li,Mina Wang,Xueqiang Peng,Yingying Yang,Qishuang Chen,Jiaxing Liu,Qing She,Jichao Tan,Chuyuan Lou,Zehuan Liao,Xuexin Li
DOI: https://doi.org/10.1002/ctm2.1384
IF: 8.554
2023-08-25
Clinical and Translational Medicine
Abstract:Messenger ribonucleic acid vaccines deliver tumour antigens to antigen‐presenting cells (APCs) for the presentation to immune cells (CD8+ T, CD4+ T) via major histocompatibility complex classes I and II. Innate immune activity can also be induced through APC‐expressed pattern recognition receptors. Antigen receptors (chimeric antigen receptors and T cell receptors) can be introduced into lymphocytes. Expressions of immunomodulatory proteins in different cell types, such as other monoclonal antibody formats, chemokine receptors, costimulatory ligands and Toll‐like receptors, etc are illustrated. . Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS‐CoV‐2 mRNA vaccines have contributed tremendously against SARS‐CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compared with conventional cancer vaccines, mRNA vaccines have significant advantages, including efficient production of protective immune responses, relatively low side effects and lower cost of acquisition. In this review, we elaborated on the development of cancer vaccines and mRNA cancer vaccines, as well as the potential biological mechanisms of mRNA cancer vaccines and the latest progress in various tumour treatments, and discussed the challenges and future directions for the field.
oncology,medicine, research & experimental